Synonyms: Ro 47-0543
Compound class:
Synthetic organic
Comment: AQ-13 is a 4-aminoquinoline antimalarial compound related to chloroquine [3,7].
The Malaria tab on this ligand page provides additional curator comments of relevance to the Guide to MALARIA PHARMACOLOGY. ![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use ![]() |
AQ-13 has completed a Phase 2 proof of concept study for the treatment of uncomplicated P. falciparum malaria in adults (NCT01614964). The per-protocol analysis of results from this clinical trial indicates that AQ-13 is similarly effective when compared to the approved combination therapy of artemether plus lumefantrine (trade name Coartem®)[6]. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT01614964 | Studies of a Candidate Aminoquinoline Antimalarial (AQ-13) | Phase 2 Interventional | Tulane University |